UBS AM
CSTL icon

UBS AM’s Castle Biosciences CSTL Stock Holding History

UBS AM’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.53M Sell
64,346
-618
-1% -$13.8K ﹤0.01% 2174
2026
Q1 		$1.59M Sell
64,964
-4,664
-7% -$153K ﹤0.01% 2146
2025
Q4 		$2.71M Buy
69,628
+12,168
+21% +$392K ﹤0.01% 1756
2025
Q3 		$1.31M Sell
57,460
-45,282
-44% -$920K ﹤0.01% 1914
2025
Q2 		$2.1M Buy
102,742
+34,711
+51% +$643K ﹤0.01% 2116
2025
Q1 		$1.36M Buy
68,031
+2,013
+3% +$49.8K ﹤0.01% 2179
2024
Q4 		$1.76M Buy
66,018
+10,486
+19% +$319K ﹤0.01% 2114
2024
Q3 		$1.58M Sell
55,532
-604
-1% -$15.4K ﹤0.01% 2164
2024
Q2 		$1.22M Buy
56,136
+24,348
+77% +$543K ﹤0.01% 2269
2024
Q1 		$704K Buy
31,788
+4,527
+17% +$98.5K ﹤0.01% 2176
2023
Q4 		$588K Hold
27,261
– – ﹤0.01% 2266
2023
Q3 		$460K Sell
27,261
-130,061
-83% -$2.27M ﹤0.01% 2328
2023
Q2 		$3.57M Hold
157,322
– – ﹤0.01% 1381
2023
Q1 		$3.57M Sell
157,322
-1,741
-1% -$42.5K ﹤0.01% 1381
2022
Q4 		$3.74M Buy
159,063
+12,717
+9% +$295K ﹤0.01% 1264
2022
Q3 		$3.82M Sell
146,346
-10,806
-7% -$303K ﹤0.01% 1294
2022
Q2 		$3.45M Sell
157,152
-20,679
-12% -$481K ﹤0.01% 1358
2022
Q1 		$7.98M Sell
177,831
-9,412
-5% -$389K ﹤0.01% 1161
2021
Q4 		$8.03M Buy
187,243
+8,588
+5% +$449K ﹤0.01% 1208
2021
Q3 		$11.9M Sell
178,655
-8,152
-4% -$574K ﹤0.01% 1023
2021
Q2 		$13.7M Sell
186,807
-6,771
-3% -$447K 0.01% 997
2021
Q1 		$13.3M Buy
193,578
+3,410
+2% +$256K 0.01% 988
2020
Q4 		$12.8M Sell
190,168
-68,969
-27% -$3.74M 0.01% 969
2020
Q3 		$13.3M Buy
259,137
+95,058
+58% +$4.23M 0.01% 869
2020
Q2 		$6.18M Buy
164,079
+8,498
+5% +$290K ﹤0.01% 1044
2020
Q1 		$4.64M Buy
+155,581
New +$4.69M ﹤0.01% 1072

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM's CSTL Position: Q2 2026 in Review

UBS AM reduced its Castle Biosciences (CSTL) stake by 0.95% in Q2 2026, selling an estimated $13.8K and leaving 64,346 shares worth $1.53M. The position accounts for ﹤0.01% of the portfolio, ranked #2174.

UBS AM first reported a position in CSTL in Q1 2020 and has held it in 26 quarters since. The position peaked at $13.7M in Q2 2021. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • UBS AM held 64,346 shares of Castle Biosciences worth $1.53M as of Q2 2026.
  • UBS AM sold 618 Castle Biosciences shares in Q2 2026, an estimated $13.8K.
  • Castle Biosciences made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2174 holding.
  • UBS AM first reported a position in Castle Biosciences in Q1 2020 and has held it in 26 quarters since.
  • UBS AM's Castle Biosciences position peaked at $13.7M in Q2 2021.
  • 176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.